Susan L. Ford

5.4k total citations
56 papers, 1.8k citations indexed

About

Susan L. Ford is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Susan L. Ford has authored 56 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Infectious Diseases, 31 papers in Virology and 14 papers in Epidemiology. Recurrent topics in Susan L. Ford's work include HIV/AIDS drug development and treatment (45 papers), HIV Research and Treatment (31 papers) and HIV/AIDS Research and Interventions (22 papers). Susan L. Ford is often cited by papers focused on HIV/AIDS drug development and treatment (45 papers), HIV Research and Treatment (31 papers) and HIV/AIDS Research and Interventions (22 papers). Susan L. Ford collaborates with scholars based in United States, United Kingdom and Belgium. Susan L. Ford's co-authors include William Spreen, Stephen C. Piscitelli, Yu Lou, Elizabeth Gould, David M. Margolis, Parul Patel, Herta Crauwels, Martin Markowitz, David A. Margolis and Krischan J Hudson and has published in prestigious journals such as Science, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Susan L. Ford

54 papers receiving 1.8k citations

Peers

Countries citing papers authored by Susan L. Ford

Since Specialization

Citations

This map shows the geographic impact of Susan L. Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan L. Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan L. Ford more than expected).

Fields of papers citing papers by Susan L. Ford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan L. Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan L. Ford. The network helps show where Susan L. Ford may publish in the future.

Co-authorship network of co-authors of Susan L. Ford

This figure shows the co-authorship network connecting the top 25 collaborators of Susan L. Ford. A scholar is included among the top collaborators of Susan L. Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan L. Ford. Susan L. Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1 2025 ·AIDS ·Ronald D’Amico, Kelong Han, Sherene Min, (unknown), (unknown), Susan L. Ford, Conn Harrington, Enrique Bernal, Johannes Lombaard, Herta Crauwels, (unknown), (unknown), (unknown), Rodica Van Solingen‐Ristea, (unknown), William Spreen	1
2	Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084 2024 ·Antimicrobial Agents and Chemotherapy ·Mark A. Marzinke, Kelong Han, Brett Hanscom, Xu Guo, (unknown), Craig W. Hendrix, Scott Rose, Elizabeth Spooner, (unknown), (unknown), (unknown), (unknown), James F. Rooney, Alex R. Rinehart, Adeola Adeyeye, Myron S. Cohen, Mina C. Hosseinipour, Susan L. Ford, Sinéad Delany‐Moretlwe	0
3	Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials 2023 ·The Journal of Infectious Diseases ·(unknown), Joseph W. Polli, Parul Patel, (unknown), Richard Grove, Vincent A. Barnett, Jeremy Roberts, (unknown), Herta Crauwels, Susan L. Ford, Rodica Van Solingen‐Ristea, (unknown), Ronald D’Amico, Bryan Baugh, Jean van Wyk	10
4	Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96 2023 ·HIV Medicine ·Shinichi Oka, (unknown), Takuma Shirasaka, Jun Yong Choi, Kim Ys, (unknown), Parul Patel, Joseph W. Polli, Susan L. Ford, Herta Crauwels, (unknown), Ronald D’Amico, Christine M. Latham, Rodica Van Solingen‐Ristea, Bryan Baugh, Jean van Wyk	1
5	2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies 2019 ·Open Forum Infectious Diseases ·Parul Patel, Susan L. Ford, Herta Crauwels, Kelong Han, Stefaan Rossenu, (unknown), Sandy Griffith, Krischan J Hudson, David M. Margolis, Mark Baker, Peter Williams, William Spreen	17
6	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial 2018 ·HIV Clinical Trials ·Miranda Murray, Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Krischan J Hudson, Britt Stancil, Susan L. Ford, Parul Patel, Alex R. Rinehart, William Spreen, David A. Margolis	54
7	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial 2017 ·The Lancet HIV ·Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Richard Elion, Deborah Goldstein, (unknown), Magdalena E. Sobieszczyk, Joel E. Gallant, Hong‐Van Tieu, Winkler G. Weinberg, David A. Margolis, Krischan J Hudson, Britt Stancil, Susan L. Ford, Parul Patel, Elizabeth Gould, Alex R. Rinehart, Kimberly Y. Smith, William Spreen	164
8	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial 2015 ·The Lancet Infectious Diseases ·David A. Margolis, Cynthia Brinson, Graham Smith, Jerome De Vente, Debbie Hagins, Joseph J. Eron, Sandy Griffith, M H St Clair, Marita Stevens, Peter Williams, Susan L. Ford, Britt Stancil, (unknown), Krischan J Hudson, Kimberly Y. Smith, William Spreen	157
9	Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam 2015 ·Xenobiotica ·Melinda J. Reese, Gary D. Bowers, Joan E. Humphreys, Elizabeth Gould, Susan L. Ford, Lindsey O. Webster, Joseph W. Polli	42
10	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans 2015 ·Xenobiotica ·Gary D. Bowers, (unknown), Melinda J. Reese, (unknown), (unknown), Stephen C. Piscitelli, Phuong Tu Huynh, David S. Wagner, Susan L. Ford, Elizabeth Gould, (unknown), Yu Lou, David A. Margolis, William Spreen	46
11	Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus 2014 ·Science ·Chasity D. Andrews, William Spreen, Hiroshi Mohri, (unknown), Susan L. Ford, Agegnehu Gettie, Kasi Russell‐Lodrigue, Rudolf P. Bohm, Cecilia Cheng‐Mayer, Zhi Hong, Martin Markowitz, David D. Ho	120
12	GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·William Spreen, Susan L. Ford, Shuguang Chen, David Wilfret, David M. Margolis, Elizabeth Gould, Stephen C. Piscitelli	117
13	Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·William Spreen, Peter Williams, David M. Margolis, Susan L. Ford, Herta Crauwels, Yu Lou, Elizabeth Gould, Marita Stevens, Stephen C. Piscitelli	96
14	HIV PrEP Dose Rationale for Cabotegravir (GSK1265744) Long-acting Injectable Nanosuspension 2014 ·AIDS Research and Human Retroviruses ·(unknown), Alex R. Rinehart, Kimberly Y. Smith, David M. Margolis, Susan L. Ford, (unknown)	4
15	Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor 2013 ·HIV Clinical Trials ·William Spreen, Sherene Min, Susan L. Ford, (unknown), Yu Lou, (unknown), Marty St. Clair, (unknown), Tamio Fujiwara	92
16	Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children 2013 ·The Pediatric Infectious Disease Journal ·Clàudia Fortuny, Dan Duiculescu, (unknown), H Garges, Mark F. Cotton, (unknown), Susan L. Ford, Mary Beth Wire, Naomi Givens, Lisa Ross, Yu Lou, (unknown), Jörg Sievers	8
17	Steady-State Pharmacokinetics, Cord Blood Concentrations, and Safety of Ritonavir-Boosted Fosamprenavir in Pregnancy 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Michelle Cespedes, Delivette Castor, Susan L. Ford, (unknown), Yu Lou, Gary E. Pakes, Judith A. Aberg	12
18	Single-Dose Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Protease Inhibitor 2006 ·Antimicrobial Agents and Chemotherapy ·Susan L. Ford, Y. Sunila Reddy, (unknown), Sharon C. Murray, P. Fernandez, Daniel S. Stein, Mark Johnson	17
19	Warfarin Resistance in a Patient with Short Bowel Syndrome 1998 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Donald F. Brophy, Susan L. Ford, Michael A. Crouch	25
20	Aplastic Anemia Associated With Prolonged High‐Dose Trimethoprim‐Sulfadiazine Administration in Two Dogs 1993 ·Veterinary Clinical Pathology ·Leslie E. Fox, Susan L. Ford, A. Rick Alleman, John W. Harvey, Bruce L. Homer	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact